How Much Did Eikon Therapeutics Raise? Funding & Key Investors

Eikon Therapeutics has developed a cutting-edge biotechnology platform that is attracting significant attention from investors. The company has successfully raised substantial funding, reflecting strong confidence in its innovative approach.

Keep reading to explore the intricacies of Eikon Therapeutics' fundraising journey and the investors backing this promising biotechnology company.

What Is Eikon Therapeutics?

Eikon Therapeutics operates within the biotechnology and pharmaceutical industry. The company is involved in developing a pipeline of therapeutic products, with locations in Millbrae, CA, New York, NY, and Jersey City, NJ.

While specific details about the founding year, founder names, and employee count are not explicitly mentioned, Eikon Therapeutics is clearly positioned as a significant player in its field, offering career opportunities and maintaining an active presence in multiple key locations.

How Much Funding Has Eikon Therapeutics Raised?

1. Seed Round
   • Amount Raised: Not publicly disclosed
   • Date: January 2019
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To establish the company and begin initial research and development efforts.
2. Series A
   • Amount Raised: USD 148,000,000
   • Date: May 2021
   • Lead Investors: The Column Group
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To hire key personnel, including CEO Roger Perlmutter, and to develop the company's super-resolution microscopy technology for drug discovery.
3. Series B
   • Amount Raised: USD 518,000,000
   • Date: January 2022
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To continue the industrialization of their live-cell imaging platform and to progress more quickly toward their mission of inventing innovative medicines.
4. Series C
   • Amount Raised: USD 106,000,000
   • Date: June 2023
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To expand their research capabilities and accelerate the development of their therapeutic pipeline.
5. Series D
   • Amount Raised: USD 350,700,000
   • Date: February 2025
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To scale up production and bring their first products to market.

Total Amount Raised: USD 1,122,700,000. Current Valuation: Not publicly disclosed.

Key Investors

• Abu Dhabi sovereign wealth fund
  • Details: A state-owned investment fund that invests globally in various sectors. It aims to diversify the economy and generate long-term financial returns.
  • Investment Focus Areas: Real estate, infrastructure, technology.
  • Notable Investments: Not publicly disclosed.
• Canada Pension Plan Investment Board
  • Details: A professional investment management organization that invests the funds of the Canada Pension Plan. It focuses on ensuring sustainable returns for Canadian retirees.
  • Investment Focus Areas: Public equities, private equities, real estate, infrastructure, fixed income instruments.
  • Notable Investments: Not publicly disclosed.
• Lux Capital
  • Details: A venture capital firm that invests in emerging science and technology ventures. It aims to support transformative innovations.
  • Investment Focus Areas: Science, technology, healthcare.
  • Notable Investments: Auris Health, Zoox, Kallyope.
• Other high-profile venture capital investors
  • Details: Participated in Eikon Therapeutics' funding rounds. Specific names are not publicly disclosed.
  • Investment Focus Areas: High-growth potential startups.
  • Notable Investments: Not publicly disclosed.
• Insurance companies
  • Details: Participated in Eikon Therapeutics' funding rounds. Specific names are not publicly disclosed.
  • Investment Focus Areas: Stable, long-term growth opportunities.
  • Notable Investments: Not publicly disclosed.

What's Next for Eikon Therapeutics?

As Eikon Therapeutics continues to innovate with its super-resolution microscopy platform, the company stands on the brink of significant breakthroughs in drug discovery. The ability to observe real-time protein interactions in living cells opens up vast opportunities for developing new treatments for serious illnesses. This technological edge positions Eikon to potentially revolutionize the pharmaceutical industry.

With substantial financial backing from high-profile investors, Eikon is well-placed to pursue further fundraising rounds. These funds will be crucial for scaling their proprietary platforms and accelerating the development of innovative medicines. However, the path forward is not without challenges. Eikon must navigate technical hurdles, intense competition, and regulatory landscapes to bring their groundbreaking drugs to market.

Use Clay to Get Funding Data

Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Eikon Therapeutics and gather other critical business insights. Sign up for free to start transforming your sales strategy today.